Case Journey: How ADCs are Transforming HER2-Low Metastatic Breast Cancer Treatment

Introducing a new and exciting video podcast experience: OncoTalks Case Journey. Tune into our debut episode as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation highlights the need for precise diagnostic approaches and the evolving landscape of breast cancer.